Head-to-head · WeighScore
Belle Health vs FMmeds
The verdict
Belle Health takes it — 77/100 to 63.2/100.
Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | FMmeds |
|---|---|---|
| WeighScore | 77/100 | 63.2/100 |
| Grade | C+ | C |
| Scorecard rank | #48 | #257 |
| Semaglutide | $119/mo | $225/mo (all doses, compounded) |
| Tirzepatide | $199/mo (all doses, 3-month plan, compounded) | $265/mo (all doses, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #48 · C+
Strengths
- Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
- Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
- Free weekly registered-dietitian sessions included
- Operating since 2017
- LegitScript Certified
Where it loses points
- $199 tirzepatide price requires a 3-month bundle commitment
- Compounded medications are not FDA-approved
- Multi-pharmacy model — formulations may differ across orders
- FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Graded #257 · C
Strengths
- All 50 states plus DC covered, stated in the Terms
- Operating LLC and full Manhattan Beach, CA address disclosed
- Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
- Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
- Flat pricing across all dose strengths — no dose-escalation surcharge
Where it loses points
- Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
- Clinical network not separately named
- LegitScript Certified, but the specific ID isn't shown
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.